Old West Investment Management LLC Takes Position in Bruker Corporation $BRKR

Old West Investment Management LLC acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 667,103 shares of the medical research company’s stock, valued at approximately $40,146,000. Bruker comprises approximately 4.3% of Old West Investment Management LLC’s portfolio, making the stock its biggest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of BRKR. Los Angeles Capital Management LLC acquired a new stake in shares of Bruker in the fourth quarter valued at approximately $26,000. Allworth Financial LP raised its holdings in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the period. Essential Partners LLC bought a new stake in Bruker in the first quarter valued at approximately $36,000. Global Retirement Partners LLC acquired a new stake in Bruker during the 2nd quarter valued at $38,000. Finally, Parallel Advisors LLC lifted its stake in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Analyst Ratings Changes

BRKR has been the subject of several recent research reports. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. UBS Group set a $60.00 price target on shares of Bruker in a research report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their target price on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Guggenheim upped their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, Wolfe Research started coverage on Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $56.64.

Bruker Price Performance

Shares of BRKR opened at $57.70 on Monday. The business has a 50-day moving average of $58.36 and a 200-day moving average of $47.04. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The company has a market capitalization of $8.79 billion, a price-to-earnings ratio of -82.43, a price-to-earnings-growth ratio of 1.76 and a beta of 1.28. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $65.30.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.